A monoclonal antibody against IGF-1, preparation method, kit and application thereof
By developing high specificity and high affinity anti-IGF-1 monoclonal antibodies, the problems of insufficient specificity and poor reliability of the existing IGF-1 detection methods are solved, and the rapid and accurate judgment of IGF-1 levels are achieved and the improvement of improvement of the improvement of IGF-1 levels is achieved. The diagnosis and treatment effects of a variety of diseases.
Patent Information
- Application Number
- CN202411284194.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-13
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-09-13
AI Technical Summary
The existing IGF-1 detection methods have insufficient specificity, poor reliability of results, and difficult to obtain high specificity IGF-1 antibodies, which affects the accurate judgment of IGF-1 levels and the diagnosis and treatment of various diseases.
A highly specific, high-affinity anti-IGF-1 monoclonal antibody was developed. Through recombinant expression vectors and immunologic mice preparation methods, monoclonal antibodies of IgG subtype were obtained for use in the IGF-1 enzyme-linked immunologic kit. and chemiluminescence method to achieve rapid and accurate judgment of IGF-1 levels in the human body.
This monoclonal antibody has high titer, strong specificity and high affinity. It can be used for rapid and accurate judgment of IGF-1 levels, and then plays an important mediating and regulatory role in various malignant tumors such as obesity and pancreatic cancer, improving detection accuracy and reliability.
Smart Images

Figure CN118791609B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to an anti-IGF-1 monoclonal antibody, a preparation method, a kit and applications thereof. Background Art
[0002] Insulin-like growth factor 1 (IGF-1) is a polypeptide protein hormone with a molecular structure similar to insulin. It plays an important role in childhood growth and has anabolic effects in adults. IGF-1 consists of a single chain of 70 amino acids connected by three intramolecular disulfide bonds. The liver, as an endocrine organ, is the main site of IGF-1 production. Growth hormone (GH) is a key factor in stimulating IGF-1 production, while malnutrition, growth hormone insensitivity, and failure of downstream signaling pathways after the lack of growth hormone receptors (including SHP2 and Stat5b) will hinder the production of IGF-1. Most (about 98%) of IGF-1 in the circulation is bound to one of six binding proteins (IGF-BPs), which help regulate the biological activity and stability of IGF-1. By binding to specific IGF receptors present on cells in various tissues, IGF-1 mediates a variety of physiological effects. IGF-1 is one of the most potent natural activators of the AKT signaling pathway, a stimulator of cell growth and proliferation, and a potent inhibitor of programmed cell death. It has been found that IGF-1 is not only related to promoting growth and differentiation, but also participates in the occurrence and development of multi-system diseases. With the deepening of research, the relationship between IGF-1 and infectious diseases has received more and more attention, and it has important significance in the diagnosis and treatment of infectious diseases.
[0003] Initially, IGF-1 level detection was mainly used in the clinic for the initial screening of GHD and acromegaly, as well as for the treatment detection and disease management of the above diseases. For many years, GH stimulation test has been used as the gold standard for determining whether pituitary GH secretion is abnormal and for diagnosing growth hormone deficiency. However, GH is regulated by hypothalamic growth hormone-releasing hormone (GHRH) and somatostatin, and is secreted in a pulsed manner. In addition, GH stimulation test has the disadvantages of cumbersome experiments, high false positive rate, and poor accuracy. Serum IGF-1 has no obvious pulsed secretion and circadian rhythm changes, and is relatively less affected by environmental factors such as pituitary pulsatile release, exercise, acute nutritional deficiency, and acute blood sugar fluctuations. It can be used as a reliable indicator to reflect the secretion status of endogenous growth hormone in the body. Determination of IGF-1 level is usually the first step in evaluating the GH / IGF-1 axis. In addition, IGF-1 also plays an important role in the prediction, diagnosis, and treatment monitoring of a variety of diseases. Several epidemiological surveys and analyses have also shown that IGF-1 is associated with a variety of tumors, such as lung cancer, and serum IGF-1 may become a powerful indicator for tumor prediction. IGF-1 was first detected and analyzed using bioassays or competitive membrane binding assays, which are laborious and nonspecific. Radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), and chemiluminescence assay (CLIA) have been used to study the role of IGF-1 and IGFBP-3 in the diagnosis and treatment monitoring of GHD and acromegaly. Although immunological analysis methods are still a common method for clinical detection of IGF-1, the anti-IGFBP-3 interference ability of kits from different manufacturers of this method is different, and the batch differences of kits from the same manufacturer are large; highly specific IGF-1 antibodies are not easy to obtain, which makes the results of various immunological analysis methods vary greatly, and the reliability of the results is questioned. Therefore, it is particularly important to develop highly specific and high-affinity IGF-1 monoclonal antibodies. Summary of the invention
[0004] In order to overcome the existing deficiencies, the present invention provides an anti-IGF-1 monoclonal antibody and a preparation method and a kit and application thereof. The monoclonal antibodies are all IgG subtypes with a titer of up to 0.64 ng / mL. The antibodies prepared by this method have high affinity and good specificity, and can be used in IGF-1 enzyme-linked immunosorbent assay kit and chemiluminescence method to make a rapid and accurate judgment on the IGF-1 level in the human body, thereby understanding the level of growth hormone.
[0005] The present invention provides an anti-IGF-1 monoclonal antibody selected from any one of the following groups:
[0006] The first group: heavy chain variable region amino acid sequence SEQ ID NO.1 and light chain variable region amino acid sequence SEQ ID NO.2;
[0007] The second group: the heavy chain variable region amino acid sequence SEQ ID NO.3 and the light chain variable region amino acid sequence SEQ ID NO.4.
[0008] Furthermore, the subtype of the monoclonal antibody is IgG.
[0009] Furthermore, the subtype of the monoclonal antibody of the first group is IgG1, and the subtype of the monoclonal antibody of the second group is IgG2a.
[0010] The present invention also provides a method for preparing the above-mentioned anti-IGF-1 monoclonal antibody, comprising the following steps:
[0011] 1) Clone the IGF-1 gene into the prokaryotic expression vector pET-28a(+) to obtain a recombinant expression vector;
[0012] 2) Transforming the recombinant vector into competent cells to obtain recombinant bacteria;
[0013] 3) culturing the recombinant bacteria, and when the OD_600 value of the culture solution is 0.6-0.8, adding IPTG to induce expression, and obtaining IGF-1 recombinant protein through separation, purification and renaturation;
[0014] 4) Immunize mice with IGF-1 recombinant protein as antigen to obtain immune spleen cells;
[0015] 5) fusing the immune spleen cells with myeloma cells to obtain hybridoma cells;
[0016] 6) Cultivating the hybridoma cells, collecting the cell culture supernatant, and purifying to obtain anti-IGF-1 monoclonal antibodies.
[0017] Furthermore, the amino acid sequence of the protein encoded by the IGF-1 gene is shown in SEQ ID NO.6.
[0018] Furthermore, the IGF-1 gene is inserted between the restriction sites Ncol and XhoI of the pET-28a(+) vector to obtain a recombinant expression vector.
[0019] Furthermore, the competent cells are BL21.
[0020] Further, the method for immunizing mice comprises:
[0021] The purified IGF-1 recombinant protein is used as an antigen and mixed and emulsified with Freund's complete adjuvant / Freund's incomplete adjuvant, that is, the antigen and Freund's complete adjuvant / Freund's incomplete adjuvant are mixed in a ratio of 1:1, and Freund's complete adjuvant is used for the first immunization, and Freund's incomplete adjuvant is used for subsequent immunizations;
[0022] Female Balb / c mice aged 6-8 weeks were selected for immunization and multiple subcutaneous injections were performed on the dorsal abdomen at a dose of 50 μg / mouse for the first immunization;
[0023] Each mouse was given a booster immunization every 2 to 3 weeks, with a dose of 25 μg per mouse;
[0024] One week after the third booster immunization, blood was collected from the eyeballs for serum titer testing, and mice with a serum titer of 1:312500 were given an intraperitoneal booster injection at a dose of 50ug per mouse to complete the immunization.
[0025] The present invention also provides a detection kit, characterized in that it contains the above-mentioned anti-IGF-1 monoclonal antibody.
[0026] The present invention also provides the use of the above-mentioned anti-IGF-1 monoclonal antibody in the preparation of a drug for diagnosing or treating a malignant tumor with abnormal expression of IGF-1.
[0027] Beneficial Effects
[0028] 1. The anti-IGF-1 monoclonal antibodies of the present invention are all of IgG subtype, with good antibody consistency and a titer of up to 0.64 ng / mL. The titer of the serum of protein-immunized mice is high. The obtained monoclonal antibodies have the advantages of strong specificity, high affinity and high titer, and can be used in IGF-1 enzyme-linked immunosorbent assay kit and chemiluminescence method to make a rapid and accurate judgment on the IGF-1 level in the human body, and thus can play an important mediating and regulatory role in various malignant tumors such as obesity and pancreatic cancer.
[0029] 2. The present invention uses E. coli as a prokaryotic expression system to construct a prokaryotic expression vector of the IGF-1 gene and induce the expression of the IGF-1 protein. E. coli is easy to generate inclusion body protein at 28°C, and the protein expression amount is high, which is beneficial to the subsequent extraction and purification of higher purity IGF-1 protein, reducing the influence of the purity of the immunogen IGF-1 protein in the animal immunization process.
[0030] 3. The animal immunization of the present invention adopts the method of multiple subcutaneous injections at the back and abdomen to improve the immune titer of mouse serum. The antibody titer produced by mice after three immunizations reaches 1:312500, which can meet the requirements of cell fusion. By subcloning the hybridoma cells three times, two high-quality hybridoma cell lines that can persistently secrete anti-IGF-1 monoclonal antibodies were screened. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 It is the electrophoresis diagram of IGF-1 protein;
[0032] Figure 2This is the electrophoresis diagram of IGF-1 monoclonal antibody. DETAILED DESCRIPTION
[0033] Example 1: Preparation and purification of IGF-1 protein
[0034] (1) The full-length sequence of human IGF-1 was obtained from NCBI, and a suitable IGF-1 gene (insulin-like growth factor 1) fragment was selected. The nucleotide sequence is shown in SEQ ID NO.5, and the IGF-1 protein sequence is shown in SEQ ID NO.6.
[0035] (2) The IGF-1 gene fragment in step (1) was inserted into the expression vector pET-28a(+) plasmid, and the restriction sites were Ncol and XhoI to construct a recombinant plasmid expression vector; the Escherichia coli was made into BL21 molecular chaperone competent cells by chemical induction, and then the constructed plasmid expression vector was transformed into BL21 molecular chaperone competent cells to obtain puncture bacteria. The puncture bacteria were spread on an LB plate containing Kan (kanamycin), and the plate was inverted and placed in a 37°C incubator for overnight culture. The plate that was cultured overnight at 37°C after transformation was taken out, and the pale yellow colonies (Escherichia coli containing the recombinant plasmid) on the plate were selected and placed in LB liquid culture medium containing Kan to culture the bacterial solution OD_600 value between 0.6 and 0.8. After completion, the bacterial solution was divided into two parts, which were used for preparing bacterial strains and PCR amplification and electrophoresis (SDS-PAGE) analysis respectively. Glycerol was added to the bacterial solution that was correctly identified by PCR and sequenced, and then glycerol was added and stored at -80°C to obtain glycerol bacteria.
[0036] (3) Protein induction preparation and purification:
[0037] IGF-1 protein induction:
[0038] Transfer 1 μL of activated bacterial solution to 10 mL of corresponding resistance LB liquid medium, culture at 37°C, 200 rpm. Transfer the cultured bacterial solution to 1 L of corresponding resistance LB liquid medium, culture at 37°C, 220 rpm, until OD_600 value is 0.6~0.8, induce with IPTG (0.5 mM) at 28°C overnight. Harvest bacteria: 8000 rpm / min 20 min. Discard supernatant. Ultrasonic disruption of bacteria: Use balanced Buffer A: 50 mM Tris, 150 mM NaCl, pH 8.5 (the pH value of the buffer is adjusted according to the isoelectric point of the protein) to resuspend the bacteria (10-15 mL volume for 1 g of bacteria), ultrasonically lyse (ultrasonication for 2 s, stop for 4 s, 60% power, 20 min), and collect the supernatant (11000 rpm / min 30 min), and filter the supernatant with a 0.22 μm or 0.45 μm filter membrane. After the supernatant and precipitate are collected, the following identification is performed. According to the identification results, choose to use the supernatant or precipitate for purification. Electrophoresis to determine the expression form: keep the following 3 samples: ① Whole bacteria after disruption: take 40μL of the bacterial suspension after ultrasound, and this sample is marked as the whole bacteria after disruption; ② Supernatant after disruption: take 100 μL of the bacterial suspension after disruption, 12000 rpm, centrifuge for 10 min, take 40 μL of supernatant to another EP tube, and this sample is marked as the supernatant after disruption; ③ Precipitation after disruption: After the supernatant is removed, the precipitate is blown away with 40 μL of 50mM Tris, 150mM NaCl, pH8.5 (the pH value of the buffer is adjusted according to the isoelectric point of the protein) solution. SDS-PAGE identification: Add 10μL of 5× Loading Buffer to the above three samples respectively, and put them into the sample cooker (95℃) for 10min. Take 10μL of each sample (untransformed BL21 bacterial solution needs to be brought as a blank control during identification). Maker adds 3μL. SDS-PAGE was performed at a constant voltage of 180 V for 40 min.
[0039] IGF-1 protein purification:
[0040] After IPTG induction and expression overnight at 28°C, the bacteria were collected, broken and centrifuged, and the resulting precipitate (inclusion body) was denatured and purified using a NI-NTA affinity chromatography column, followed by dialysis and renaturation to prepare a high-purity IGF-1 protein. The electrophoresis results of the renatured IGF-1 protein are shown in Figure 2. Figure 1 As shown, M represents Marker, 1 represents R (reduced electrophoresis form), 2 represents N (non-reduced electrophoresis form), and 4%-20% SDS-PAGE (gel product number: KGMG0420-12) is used.
[0041] Example 2: Immunization of mice with IGF-1 recombinant protein
[0042] The IGF-1 protein purified in Example 1 was used as an immunogen, and 5 female Balb / C mice aged 6-8 weeks and weighing 18-20g were selected. For the first immunization, Freund's complete adjuvant (SIGMA, Cat#F5881) and IGF-1 recombinant protein 50ug / mouse were mixed in equal volumes, fully emulsified, and injected subcutaneously at multiple points in the back and abdomen, 200uL / mouse. Three weeks after the first immunization, Freund's incomplete adjuvant (SIGMA, Cat#F5506) and IGF-1 recombinant protein 25ug / mouse were mixed in equal volumes for the second immunization, and injected subcutaneously at multiple points in the back and abdomen, 200uL / mouse. Two weeks after the second immunization, Freund's incomplete adjuvant (SIGMA, Cat#F5506) and IGF-1 recombinant protein 25ug / mouse were mixed in equal volumes for the third immunization, and injected subcutaneously at multiple points in the back and abdomen, 200uL / mouse. One week after the three immunizations, blood was collected from the eyeballs for serum titer testing. Mice with a serum titer of 1:312500 were selected for booster immunization, and 50ug of immunogen was injected intraperitoneally per mouse. Three days later, the spleens of the mice were fused. The titer test results of the three immunization blood collection tests of 5 mice are shown in Table 1.
[0043] Table 1: IGF-1 titer test results of three blood samplings in mice
[0044]
[0045] Example 3: Hybridoma cell fusion
[0046] Cell fusion: On the day of fusion, take the boosted immunized mice, dislocate the neck and immerse in 75% alcohol. Cut the skin and peritoneum on the clean bench for 3-5 minutes and take the spleen. After grinding, pass through a 70um cell screen (BD Falcon, Cat# 352350). Spleen cells and SP2 / 0 cells are fully washed with blank DMEM (Gibco, Cat# 10566-016) and counted. Then, spleen cells and SP2 / 0 are mixed in a ratio of 5:1, centrifuged at 1500r for 5 minutes, the supernatant is discarded, and 125uL of electrofusion buffer (Celetrix, cat# 1221) is added. Take 400uL of the mixed high-concentration cell mixture and add it to a 400uL electroporation tube (Celetrix, cat# 1221). The 400uL electroporation tube is placed in a special electroporation tube centrifuge adapter in a 50mL centrifuge tube. Use another ordinary 50mL centrifuge tube for balancing and add 36mL of water. It must be centrifuged in a horizontal centrifuge at a speed of 1400rpm for 2min. After centrifugation, place the electroporated tube in the electrofusion instrument with an energy parameter of 2300v for 2min. After the electroporation, let it stand for 3min and place it in the fusion medium (20% FBS + 80% DMEM) for 2h of recovery culture, and finally spread it on 15 96-well cell culture plates.
[0047] Example 4: Hybridoma cell screening
[0048] Fusion screening and subcloning: 7 days after fusion, replace the fusion medium with 10% FBS medium. 3-7 days after the medium change, wait until the average cell density of the 96-well plate is 30%-70% before fusion detection. Use IGF-1 recombinant protein as the screening source, use 10mM phosphate buffer as the coating solution to coat the 96-well enzyme-labeled plate, perform Elisa indirect detection, and pick out cells in positive wells with a cut off value greater than 0.5. Pick out the positive cell lines for limiting dilution, count and take 100 cells per plate, and spread them on a 96-well plate. Spread one plate for each cell line. After 7 days of culture, single cells will proliferate and grow into single clones. Observe the cell morphology and state under a microscope, and preferentially pick out the cell supernatant from the monoclonal, appropriate size, and good state of the cell cluster. Use IGF-1 recombinant protein as the screening source, use 10mM phosphate buffer as the coating solution, perform Elisa indirect detection, and pick out cells in positive wells with a cut off value greater than 1.0. When the cell density is about 50%, subcloning and subclone detection are performed again to pick out positive monoclones. After a total of 3 subclones and subclone detections, the monoclonal cell lines that are fully positive in the third subclone are retained and transferred to a 24-well cell culture plate.
[0049] Example 5: Preparation of IGF-1 monoclonal antibody
[0050] Serum-free expression and monoclonal antibody purification: Preparation of monoclonal antibody by serum-free expression: The positive high-value monoclonal cell lines selected by three subclonings are expanded from 24 wells to 6 wells, and then expanded from 6 wells to T75, and then cryopreserved and serum-free expression pilot production can be carried out. When the confluence of IGF-1 hybridoma cells in T75 reaches about 75%, it is replaced with SFM serum-free medium (Gibco, cat#12045076) 50mL culture system, and cultured statically for 7 days. When all hybridoma cells are apoptotic, the supernatant is taken and the titer of the secreted monoclonal antibody in the supernatant is detected. IGF-1 recombinant protein is used as the screening source, 10mM phosphate buffer is used as the coating liquid to coat the 96-well ELISA plate, and the IGF-1 serum-free expression supernatant is used as the primary antibody. A 5-fold gradient dilution is made from the original multiple, with a total of 7 gradients, and the Elisa indirect method is used for detection. Cell lines with high titer and good gradient are selected as the superior candidate strains. Monoclonal antibody purification: centrifuge the SFM cell culture supernatant in the cell culture square bottle at 8000r / min, 10min, 4℃, take the supernatant, filter with a syringe and a 0.45um microporous filter, and take 50uL of sample. Prepare the Pro A column while processing the supernatant. According to the column efficiency (i.e., the amount of antibody that can be bound per milliliter of Pro A column) and the volume of the serum-free expression supernatant to be purified (the amount of antibody contained is generally: 0.1-5mg / mL), load Pro A into the column. Generally, 50mL of supernatant is added to the gravity column of the 0.5-1mL system of Pro A beads (Qianchun, cat#A41201-08). Pass the column with sterile ultrapure water and wash away the column preservation solution. After washing the column with sterile ultrapure water, pass the column with column balance solution, using a volume of 10-15 times the column volume, and the speed should not be too fast. Sample loading: pass the SFM supernatant filtrate obtained by filtration through the Pro A column and collect the flow-through. After the sample is loaded, the impurities can be washed with the balance solution, that is, the balance solution is passed through the Pro A column, and the concentration of the wash solution is determined by A280 to determine whether it is eluted. Collect the wash solution. Elution: After the washing is completed, the wash solution is replaced with the elution solution, 0.5mL (1.0mL) / tube for segmented elution, and a total of 5 elution tubes are collected. In a 1.5mL centrifuge tube, add the neutralizing solution Tris, pH9.0 according to the volume of the elution solution (first determine the volume ratio to reach pH7.0). During the elution process, use A280 to determine whether there is protein. If the concentration is lower than 0.2mg / mL, it can be discarded. Finally, mix and roughly calculate the yield. Dialyze with 1×PBS (pH7.0) at 4℃ overnight, and change the solution twice the next day. After the dialysis is completed, sterile filter the antibody, determine the concentration, and store it as needed. Wash the column: The order is: 10 column volumes of elution solution, 10 column volumes of balance solution, 10 column volumes of ultrapure water, and an equal volume of 20% ethanol for storage. The electrophoresis results of the purified monoclonal antibody are as follows: Figure 2 As shown, #8 represents the monoclonal antibody produced by A23011H-8, and #10 represents the monoclonal antibody produced by A23011H-10.
[0051] Example 6: IGF-1 mAb subtype identification
[0052] Identification of monoclonal antibody subtypes: Take the serum-free expression supernatants of 2 strains for monoclonal antibody subtype identification. Purchase a commercial typing kit (sigma, cat#ISO2-1KT). Coat the 6 subtypes of monoclonal antibodies in the typing kit overnight. Detect the serum-free expression monoclonal antibody samples to be identified according to the instructions. Finally, determine the subtypes of each monoclonal antibody, and the specific identification results are shown in Table 2.
[0053] Table 2: IGF-1 monoclonal antibody isotype identification results
[0054]
[0055] Example 7: IGF-1 monoclonal antibody titer detection
[0056] The titer of the monoclonal antibody purified in Example 5 was detected by indirect ELISA, and the specific steps were as follows:
[0057] (1) Package board
[0058] IGF-1 Antigen 2ug / mL, 100uL / well, diluted with 1×PBS, incubated at 37℃ for 2h;
[0059] (2) Washing the plate
[0060] 1×PBST, 300uL / well, wash once;
[0061] (3) Closed
[0062] 1×PBST was used as the mother solution, and 1% BSA was prepared as the blocking solution, 200uL / well, incubated at 37℃ for 2h;
[0063] (4) Washing the board
[0064] 1×PBST, 300uL / well, wash once;
[0065] (5) Add IGF-1 monoclonal antibody
[0066] Monoclonal antibody 10ug or more, 5-fold dilution, 100uL / well, each plate with positive and negative control wells, incubate at 37℃ constant temperature box, incubate for 40min;
[0067] (6) Washing the board
[0068] 1×PBST, 300uL / well, wash 4 times;
[0069] (7) Add secondary antibody
[0070] GAM-HRP 1:5000, prepared with 1×PBST, 100uL / well, incubated at 37℃ for 40min;
[0071] (8) Color rendering
[0072] Add color developing solution, 100uL / well, and develop color for 10min;
[0073] (9) Termination
[0074] Add stop solution, 50uL / well;
[0075] (10) Plate reading
[0076] Within 3 minutes of color development, the plate was read at 450 / 620nm dual wavelength, and the test results were exported to Excel tables;
[0077] (11) Processing data
[0078] (12) Results analysis
[0079] The results of Elisa test are shown in Table 3. The titer of the monoclonal antibody is around 0.64 ng / mL, which is high.
[0080] Table 3: IGF-1 monoclonal antibody titer test results
[0081]
[0082] Example 8: IGF-1 monoclonal antibody affinity detection
[0083] The affinity of the monoclonal antibody purified in Example 5 was detected by capture ELISA, and the specific steps were as follows:
[0084] (1) Package board
[0085] GAM (Jackson, cat#115-005-072), 2ug / mL, 100uL / well, diluted with 1×PBS, incubated at 37°C for 2h;
[0086] (2) Washing the plate
[0087] 1×PBST, 300uL / well, wash once;
[0088] (3) Closed
[0089] 1×PBST was used as the mother solution, and 1% BSA was prepared as the blocking solution, 200uL / well, incubated at 37℃ for 2h;
[0090] (4) Washing the board
[0091] 1×PBST, 300uL / well, wash once;
[0092] (5) Add IGF-1 monoclonal antibody
[0093] Monoclonal antibody 10ug or more, 5-fold dilution, 100uL / well, each plate with positive and negative control wells, incubate at 37℃ constant temperature box, incubate for 40min;
[0094] (6) Washing board
[0095] 1×PBST, 300uL / well, wash 4 times;
[0096] (7) Add biotin-labeled IGF-1 antigen (IGF-Biotin) at a working concentration of 1:300 and incubate at 37°C for 40 min.
[0097] (8) Washing board
[0098] 1×PBST, 300uL / well, wash 4 times;
[0099] (9) Add SA-HRP, 1:10000, prepared in 1×PBST, 100uL / well, incubate at 37°C for 40min;
[0100] (10) Washing plate
[0101] 1×PBST, 300uL / well, wash 4 times;
[0102] (11) Color rendering
[0103] Add color developing solution, 100uL / well, and develop color for 10min;
[0104] (12) Termination
[0105] Add stop solution, 50uL / well;
[0106] (13) Plate reading
[0107] Within 3 minutes of color development, the plate was read at 450 / 620nm dual wavelength, and the test results were exported to Excel tables;
[0108] (14) Processing data
[0109] (15) Results analysis
[0110] The results of Elisa test are shown in Table 4. The affinity of the monoclonal antibody is about 0.64 ng / mL, which is higher than that of the reference positive antibody.
[0111] Table 4: Affinity test results of IGF-1 monoclonal antibodies
[0112]
[0113] Example 9: Determination of monoclonal antibody variable region sequences
[0114] The monoclonal antibody obtained in Example 5 was sent to Anhui General Biotechnology Co., Ltd. for sequencing. The amino acid sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody produced by A23011H-8 were determined to be SEQ ID NO.1 and SEQ ID NO.2, respectively; the amino acid sequences of the heavy chain variable region and the light chain variable region of the monoclonal antibody produced by A23011H-10 were determined to be SEQ ID NO.3 and SEQ ID NO.4, respectively.
[0115] The amino acid sequence of the heavy chain variable region of the monoclonal antibody produced by A23011H-8 (SEQ ID NO.1):
[0116] QVQLQQPGAALVKPGASVKLSCKASGYSFTGFWMHWMKRGPEQGLEWIGEINPSSGHANYNEKFRHRATLTVDTSSSTAYMQLNSLTSEDSAVFYCAADTYDYALDYWGHGTSVTVSS
[0117] The amino acid sequence of the light chain variable region of the monoclonal antibody produced by A23011H-8 (SEQ ID NO.2):
[0118] DIVMTQSPLTLSVSLGQPASISCKSSQSLLDSDGRTFLNWFLWRPGQSPQRLISLVSKLDSGVPDRFTGSGSGTDFTLKISRVQAEDLGVYYCWQGTHFPLTFGAGTKLELK
[0119] The amino acid sequence of the heavy chain variable region of the monoclonal antibody produced by A23011H-10 (SEQ ID NO.3):
[0120] EVQLQQSGPELMKPGASVKISCKASGYSFTSYYMHWVKQSHGKSLEWIGYIDPFNGGTNYNQKFKGKATLTVDKSSSTAYMHLSSLTSEDSAVYYCAPSGGNHFALDYWGQGTSVTVSS
[0121] The amino acid sequence of the light chain variable region of the monoclonal antibody produced by A23011H-10 (SEQ ID NO.4):
[0122] DVLMTQTLFSLPVSLGDQASISCRSSQSIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFFGVPDRFSGSGSGTDFTLKISRVEAEDLGVYYCFQGSHVPWTFGGGTKLEIK
[0123] IGF-1 nucleotide sequence (SEQ ID NO.5):
[0124] ATGGGTCCTGAAACCCTGTGTGGTGCAGAACTGGTGGATGCCCTGCAGTTTGTTTGCGGCGATCGCGGCTTTTATTTTAATAAGCCGACCGGCTATGGTAGCAGTAGTCGCCGCGCCCCGCAGACCGGTATTGTGGATGAATGCTGCTTTCGTAGCTGTGATCTGCGTCGTCTGGAAATGTATTGTGCACCGCTGAAACCGGCAAAAAGCGCCCATCATCATCATCACCATTAA
[0125] IGF-1 amino acid sequence (SEQ ID NO.6):
[0126] MGPETLCGAELVDALQFVCGDRGFYFNKPTGYGSSSRRAPQTGIVDECCFRSCDLRRLEMYCAPLKPAKSAHHHHHH。
Claims
1. An anti-IGF-1 monoclonal antibody, characterized in that: Select from any of the following groups: The first group: heavy chain variable region amino acid sequence SEQ ID NO.1 and light chain variable region amino acid sequence SEQ ID NO.2; The second group: the heavy chain variable region amino acid sequence SEQ ID NO.3 and the light chain variable region amino acid sequence SEQ ID NO.
4.
2. The anti-IGF-1 monoclonal antibody according to claim 1, characterized in that The subtype of the monoclonal antibody is IgG.
3. The anti-IGF-1 monoclonal antibody according to claim 2, characterized in that The subtype of the monoclonal antibodies of the first group is IgG1, and the subtype of the monoclonal antibodies of the second group is IgG2a.
4. A detection kit, characterized in that: A monoclonal antibody comprising the anti-IGF-1 according to any one of claims 1 to 3.
5. Use of the anti-IGF-1 monoclonal antibody according to any one of claims 1 to 3 in the preparation of a reagent for detecting malignant tumors with abnormal expression of IGF-1.
